NEW YORK , Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of REGENXBIO Inc. ("Regenxbio" or the "Company") (NASDAQ: RGNX). Such investors are advised...
ROCKVILLE, Md. , Feb. 9, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding...
New York, New York--(Newsfile Corp. - February 9, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into REGENXBIO Inc. ("REGENXBIO Inc.") (NASDAQ: RGNX) concerning potential...
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of REGENXBIO Inc. (“Regenxbio” or “the Company”) (NASDAQ:...
New York, New York--(Newsfile Corp. - February 2, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into REGENXBIO Inc. ("REGENXBIO Inc.") (NASDAQ: RGNX) concerning potential...
NEW YORK , Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of REGENXBIO Inc. ("Regenxbio" or the "Company") (NASDAQ: RGNX). Such investors are advised...
New York, New York--(Newsfile Corp. - January 29, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into REGENXBIO Inc. ("REGENXBIO Inc.") (NASDAQ: RGNX) concerning potential...
ROCKVILLE, Md. , Jan. 28, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy,...
ROCKVILLE, Md. , Jan. 11, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) highlighted progress and upcoming anticipated milestones across its pipeline of AAV gene therapies for rare and retinal...
ROCKVILLE, Md. , Dec. 18, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present at the 44 th Annual J.P. Morgan Healthcare Conference.